Taken together, the newly discovered upregulation of glutamate production via the glutaminase II pathway in cancer upon GLS1 inhibition and the off‐target effects of global glutamine antagonism strongly suggest a need for the development of a specific GTK inhibitor to combine with GLS1 inhibition for cancer therapy. The gene discussed is GLS; the disease is cancer.